Brand profile · Biotechnology Research

GPN Vaccines

GPN Vaccines runs a Biotechnology Research operation from Yarralumla, Australian Capital Territory. Ownership is publicly held; it publishes at gpnvaccines.com. It holds one address on record, all in Australia. The record counts 28 people. One Australian registration (ABN) is a confirmed match. The latest round on record is Series B at US$12.0M. The record links eight similar brands, most of them in Biotechnology Research.

gpnvaccines.com LinkedIn

Profile live Public Company Founded 2017 1 entity ABN 1 office country US$ 12.0M Series B
Registry verified · ABR
Counted staff
28
self-reported 11–50 band
Founded
2017
9 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
7
Series B · Jul 2024 · US$ 12.0M
Company type
Public Company
self-reported
Use this profile Compare Your shortlist

Legal entity

1 brand → 1 confirmed entity

  • GPN VACCINES LTD

    ABN89621789008

    ACTHigh confidenceMatched on exact nameABR

Legal entities

GPN Vaccines: 1 registry entityGPN Vaccines is linked to 1 registry entity: GPN VACCINES LTD (ABN 89621789008, candidate).GPN VaccinesGPN VACCINES LTDABN 89621789008Candidate · High confidence
Show as table
GPN VACCINES LTDABN 89621789008
Confirmed matches0 of 1

A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.

Description

GPN Vaccines is a clinical-stage company focused on creating innovative vaccines that offer robust protection against the world's most important bacterial pathogens.

Locations

Australiaprimary

Country footprint

Offices in 1 countryCountry footprint: 1 country, primary AU. Codes: AU.1 countryprimary AUAU
Show as table
Countries1
Primary countryAU

All codes: AU

Addresses

  • AU14/65 Musgrave St; Yarralumla, Australian Capital Territory 2600Primary

Grid intelligence Members

Funding

Last round · 6 July 2024US$ 12.0MSeries B · investor: Forepont Capital Partners
Rounds7
Round typeSeries B · venture round
Amount (USD)12,000,000
Stage rank4
Investors named2
Since last round1 yr 6 mo

Funding

7 funding roundsFunding timeline. Latest round 6 Jul 2024: Series B, US$ 12.0M.20172026Series BUS$ 12.0M7 rounds
Show as table
Rounds7
Axis2017 to 2026
Series B · 6 Jul 2024US$ 12.0M

Dated rounds only. The axis ends at the date this profile was last observed, not at today.

Spending power

TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.

Spending power

Notify me about spending power

Signals & hiring

Hiring, headcount and registry-change signals, streamed to members.

Latest signal
Hiring activity
Headcount trend
Notify me about signals

Financials

Registry-filed capital and financial indicators, standardised by TheGrid.

Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
Notify me about financials

People & contacts

4 employee profiles on record · names withheld.

Counts only. No names are stored here, and none are served.

Notify me about contacts Tell us who you need to reach and we will tell you when a consented source is live.

FAQ

Which legal entity operates under GPN Vaccines?

One Australian Capital Territory entity on the ABR. GPN VACCINES LTD (ABN 89 621 789 008), high confidence.

How many people work at GPN Vaccines?

The record holds 28 counted staff profiles at January 2026, inside the self-reported 11–50 band.

Where does GPN Vaccines have offices?

One address on record, Australia only. Primary: 14/65 Musgrave St, Yarralumla, Australian Capital Territory 2600.

Has GPN Vaccines raised funding?

Seven rounds. Latest 6 July 2024: Series B, US$12,000,000, investor Forepont Capital Partners.

Which companies are listed alongside GPN Vaccines?

11 profiles list GPN Vaccines as a peer — 84th percentile in Biotechnology Research. It lists ten peers of its own. GroPep® Bioreagents Pty Ltd and ARCS Australia list it back.

What is GPN Vaccines's website?

gpnvaccines.com